Replies to post #169184 on Biotech Values

[oc631]

It's just strange announcing only GT2 results in the PR considering it's a GT2/GT3 study.

The GT3 SVR rates are listed outside the LONESTAR-2 title heading within the PR. Twelve-week (n=24), Sofo/PegRiba SVR rates of 83% puts the option within the same range as 24-weeks of oral.